Oral contraceptive (OC) use has been consistently linked to increased risk of infl ammatory bowel disease. Nonetheless, a specifi c role of OC in the natural history of ulcerative colitis (UC) is unknown.
INTRODUCTION
Ulcerative colitis (UC) is a chronic infl ammatory disorder of the gastrointestinal tract with heterogeneous disease presentation. In nearly 20% of cases, the initial presentation is an acute severe colitis requiring hospitalization, whereas nearly 50% of patients may never require hospitalization related to their disease (1) (2) (3) . Although the pathophysiology of the disease remains largely unknown, a number of novel environmental and genetic factors have recently been linked to the onset of UC, further expanding our knowledge of potential key biologic pathways involved
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in development of the disease (4) (5) (6) (7) . Despite these advances in disease etiology, little is known about factors that are associated with disease progression.
Because a signifi cant number of women in reproductive age with UC may consider use of oral contraceptives (OCs), understanding the impact of these medications on progression of UC can help inform clinical recommendations. Previously, we have shown an association between long-term use of OCs, particularly the combination type, and risk and progression of Crohn's disease (CD) ( 8, 9 ) . However, the data on the eff ect of OC on risk and progression of UC are sparse. Although some studies have shown an association between OC use and risk of UC, most recent meta-analysis as well as our recent cohort study did not support this association ( 9, 10 ) . Nonetheless, a specifi c role for OC use on progression of UC is unclear.
We therefore sought to examine the association between OC use and UC progression defi ned by need for surgery or use of steroids or anti-tumor necrosis factor (anti-TNF) using a large population-based cohort in Sweden. To our knowledge, this is the fi rst study examining the association between OC use and disease progression among women with established UC. Because of the availability of detailed and updated information on dispensed prescriptions, inpatient, and hospital-based ambulatory care visits, this cohort provided us with a unique opportunity to explore such associations.
METHODS
Study population
Th e Swedish health-care system is tax funded and off ers universal access including prescription coverage. Th e Swedish National Board of Health and Welfare has collected individual-level data on hospital discharges on a countywide level since 1964 (nationwide since 1987) ( 11 ) . Each record, organized according to an individual's personal identity number, includes date of birth, sex, dates of hospital admission, hospital department, and discharge diagnoses (including surgical procedures), coded according to the International Classifi cation of Diseases ( 12 ) . Since 2001, this registry was expanded to include specialized outpatient care ( 11 ) .
Our study population included women between the ages of 16 (typical earliest age used in prior studies in Sweden ( 13, 14 ) ) and 51 years (median age of menopause) ( 15 ) with at least two inpatient or outpatient encounters with a primary or secondary diagnosis of UC (ICD9: "556" or ICD10: "K51") aft er January 2003. We selected January 2003 as our study starting point to allow for a 2-year lag between introduction of outpatient data in the National Patient Register and identifi cation of prevalent cases of UC previously not captured through hospitalizations. Participants with any diagnoses codes for UC or CD at any time before 2003 (1964-2003) or those who had a change in their diagnosis from UC to CD or indeterminate colitis (ICD10: "K52.3") at any time during follow-up were excluded from the study. Th e accuracy of ICD coding for disease ascertainment for the inpatient component of the National Patient Register has been previously validated, with a positive predictive value of 85-95% ( 16 ) . In addition, a recent study from this cohort has shown that this defi nition yields a stable and reliable prevalence for UC, comparable to those previously reported in Scandinavia and Canada ( 17 ) . Although there has not been a formal validation study in Sweden about the accuracy of capturing incident cases of UC, preliminary results from our ongoing validation study showed a positive predictive value of >93% with ≥2 infl ammatory bowel disease encounters within the registry.
Primary exposure and other covariates
Since 1 July 2005, information on all dispensed prescriptions for the entire Swedish population, including date of redemption, amount of drug, and dosage, has been collected in the Swedish Prescribed Drug Register ( 18 ) . Specifi cally, sale information about each prescription for all individuals is directly transferred from the cashier to the registry. Th e registry is virtually complete for the entire population, with identity data missing for <0.3% of all outpatient prescribed medications ( 18 ) . Information on the defi ned daily dose (DDD) is also available for each prescription. DDD is a statistical measure of drug consumption, defi ned by the World Health Organization to standardize the comparison of drug usage between diff erent drugs or between diff erent health care environments. Categories of DDD use were defi ned based on approximate annual or biannual use of medications. OC use was identifi ed through Anatomical Th erapeutic Chemical codes (ATC) of G03AA or G03AB (combined hormonal contraceptives) and G03AC (progestin only). Th ese ATC codes have previously been used to describe patterns of OC use in Sweden ( 13 ) . Information on OC use was updated monthly and entered in our models as current, past, or nonusers. In addition, we calculated and updated the cumulative duration of intake of OC and cumulative DDD of use from July 2005 (earliest time prescription data were available) for each participant by adding the number of months and DDD use over follow-up time, respectively. Information on UC-related medications including 5-aminosalicylic acid, steroids, thiopurines (azathioprine and 6-mercaptipurines), and methotrexate, and anti-TNF therapy (infl iximab and adalimumab) were also obtained from the prescription registry ( Supplementary Table S1 online). As infl iximab is primarily infused in hospitals, data on infl iximab use were not available nationwide. However, in the Stockholm county, which accounts for 20% of population in Sweden, starting in 2007, information on outpatient infusions of biologics including infl iximab in the hospital was collected (European commission granted approval of infl iximab for treatment of UC in March of 2006). We obtained data on education level from the longitudinal integrated database for health insurance and labor market studies (LISA) that integrates annually updated administrative information from the labor market and educational and social sectors from 1990 onward on all individuals ≥16 years old registered as residents in Sweden ( 19 ) . Data from LISA are linked to patients with diagnosis of UC using Swedish resident's unique personal identity number. Information on age, sex, dates of birth, death, or immigration was collected from the Swedish Total Population Register kept by Statistics Sweden ( 20 ) . We also calculated and updated the number of UC-related encounters (both inpatient and outpatient)
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for each participant during the follow-up. Finally, information on parity was collected from the Swedish Medical Birth Register that includes information on >98% of all births in Sweden since 1973. Information is prospectively collected by midwives from standardized prenatal, obstetrical, and neonatal records ( 21 ) . We adjusted for parity in our sensitivity analyses because it may account for diff erences in disease severity as women with more severe disease are less likely to become pregnant.
Outcome ascertainment
Information on UC-related surgery was obtained from surgical procedure codes available nationwide in the registry since 1987. Th e validity of surgical procedure coding in the National Patient Register has been reported to be high (positive predictive value >85%) ( 22 ) . For UC-related surgeries, we used "JFH" subcodes referring to open or laparoscopic colectomy (subtotal or proctocolectomy) and ileostomy with or without creation of ileal pouch-anal anastomosis. We defi ned need for steroid as the fi rst dispensed prescription for steroids (ATC codes="H02AB06" and "H02AB07" for oral prednisolone) at least 90 days aft er start of follow-up. Similarly, fi rst anti-TNF use was ascertained from prescription registry for adalimumab (ATC code=L04AB02) and Stockholm anti-TNF registry for infl iximab as described above.
Statistical analysis
Person-time for each participant was calculated from 1 July 2005 or second UC-related encounter, whichever came last, to the date of fi rst UC-related surgery, death from any cause, date of emigration, or 31 December 2014, whichever came fi rst. We used Cox proportional hazards modeling adjusting for covariates to calculate adjusted hazard ratios (aHRs) and 95% confi dence interval (CIs). As there could be diff erences in the duration of disease at the time of study entry in July of 2005, we adjusted for duration of disease, which was calculated from the time of fi rst UC-related encounter (2003) (2004) (2005) to the study entry, in our multivariable analyses. In addition, to account for secular trends in patterns of OC use over follow-up time, we stratifi ed all analyses by calendar year. Finally, we explored the possibility that the eff ect of OC use on risk of surgery or steroid prescription may be modifi ed by age of diagnosis (e.g., defi ned as age at the time of second UC-related encounter) and parity by entering OC use and binary age of diagnosis (high vs. low based on median value) or parity (parous vs. nulliparous) in our models as a multiplicative interaction terms. We used SAS version 9.4 (Cary, NC) for these analyses. All P values were two sided and <0.05 was considered statistically signifi cant. Th e study was approved by the regional ethics committee at Karolinska Institutet (Stockholm, Sweden).
RESULTS
Th rough December of 2014, we identifi ed 162 incident surgeries among 6,104 UC patients who contributed 31,421 person-years with a median follow-up of 60 months. Compared with non users, past and current users were younger and more likely to have had >12 years of education ( Table 1 ) . However, the county of residence, number of UC-related encounters over follow-up, and patterns of UC-related medication use were similar across the groups ( Table 1 ) .
OCs and risk of surgery
Compared with nonusers, the age-adjusted HRs of surgery were 0.94 (95% CI, 0.64-1.40) for past users and 0.72 (95% CI, 0.46-1.15) for current users ( Figure 1 ). Th ese estimates were not materially altered aft er adjusting for other covariates (aHR=0.79 (95% CI, 0.52-1.18) among past users and aHR=0.74 (95% CI, 0.46-1.18) among current users, P trend =0.17). In addition, the risk of surgery did not appear to increase with longer duration of use ( P trend =0.28) or higher number of DDD ( P trend =0.70) ( Figure 1 ). Specifi cally, compared with nonusers, the aHRs of surgery were 0.66 (95% CI, 0.39-1.13) with ≤1 year of use, 0.88 (95% CI, 0.56-1.39) with >1 and ≤3 years of use, and 0.74 (95% CI, 0.43-1.27) with >3 years of use ( Figure 1 ) . Similarly, compared with nonusers, the aHRs of surgery were 0.53 (95% CI, 0.29-0.99) with ≤300 DDDs, 0.83 (95% CI, 0.52-1.33) with >300 and ≤900 DDDs, and 0.94 (95% CI, 0.60-1.47) for >900 DDDs of use ( Figure 1 ).
OCs and risk of steroid prescription
We also explored the association between OC use and risk of steroid use. Compared with nonusers, the age-adjusted HRs of receiving a steroid prescription were 0.87 (95% CI, 0.67-1.14) for past users and 0.93 (95% CI, 0.70-1.24) for current users. Th ese estimates were not signifi cantly altered in multivariable analyses; aHRs of steroid prescription were 0.86 (95% CI, 0.66-1.12) among past users and 0.94 (95% CI, 0.71-1.26) among current users ( P trend =0.57) ( Figure 2 ). In addition, longer duration of use and increased number of prescriptions of OC were not associated with increased risk of steroid prescription ( P trend =0.68 and 0.63, respectively) ( Figure 2 ). Specifi cally, compared with the nonusers, the aHRs of steroid prescription were 1.21 (95% CI, 0.89-1.67) among UC women with >3 years of OC use and 1.17 (95% CI, 0.89-1.55) for >900 DDD use of OC.
Types of OCs and risk of steroid prescription and surgery
We explored the possibility that the association between OC and disease progression may diff er according to the type of OC use and therefore evaluated the independent eff ect of combinationtype and progestin-only OC on risk of UC complications. Similar to our primary analyses, we did not observe an association between progestin or combination-type OC and risk of surgery. Specifi cally, compared with nonusers, the aHRs of surgery among women who had used OC for >2 years were 0.84 (95% CI, 0.54-1.31) for combination-type OC and 1.02 (95% CI, 0.58-1.80) among progestin-only-containing contraceptives. In addition, the risk of surgery did not increase with higher number of DDD use of combination-type OC ( P trend =0.53) or the progestin-only type ( P trend =0.94). Similar to our main analyses, longer duration of combination or progestin-only-containing types of OC use was not associated with increased risk of steroid prescriptions ( P trend =0.35 and 0.89, respectively).
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Exploratory and sensitivity analyses
As use of anti-TNF therapy also represents a signifi cant escalation of treatment for patients with established UC, we explored the association between OC use and risk of anti-TNF initiation in the Stockholm county, where detailed and updated information on infl iximab infusions were available starting in 2007 (shortly aft er approval of infl iximab for UC in Europe). Data on other injectable anti-TNF therapy including adalimumab use were obtained from prescription registry. Compared with nonusers, the aHR of anti-TNF use was 0.83 (95% CI, 0.59-1.18) among current OC users. In addition, longer duration or cumulative DDD use of OC were not associated with increased risk of anti-TNF use ( P trend =0.97 and 0.98, respectively).
As voluntary childlessness may alter women's decision to use OC, we performed stratifi ed analyses according to parity (nulliparous vs. multiparous) and observed no eff ect modifi cation ( P interaction =0.85). As there were signifi cant diff erences in age of diagnosis according to OC status likely because of introduction of prescription registry in 2005 and variations in use according to age even among premenopausal women, we assessed the eff ect of OC on UC progression according to strata defi ned by age of diagnosis (e.g., age at second UC-related encounter) and observed no eff ect modifi cation ( P interaction =0.55). Specifi cally, the aHR of surgery among current OC users in women with age of diagnosis < 33 years (mean age of diagnosis and typical age with highest prevalence of OC use) was 1.02 (95% CI, 0.50-2.10). Similarly, we observed no eff ect modifi cation by age at second UC-related encounter on the risk of steroid prescription with OC use (All P interactions > 0.29). Specifi cally, the aHR of steroid prescription among current OC users in women with age of diagnosis < 33 years was 0.94 (95% CI, 0.63-1.39).
We considered the possibility that women who were OC users in 2005 may have been using for varying durations (e.g., left truncation bias) and thus conducted sensitivity analysis in which we included only women who were diagnosed with UC aft er 2005 (both fi rst and second UC-related encounters occurred aft er 2005). In addition, we excluded women who were users during the fi rst year the prescription registry was started 
DISCUSSION
In a nationwide cohort study, we found no association between OC use and risk of UC progression ( 8 ) . Specifi cally, we did not identify an association between OC use and risk of surgery and steroid or anti-TNF prescription among women with established UC.
In animal models, exogenous estrogen modulates intestinal barrier function ( 23, 24 ) . In addition, endogenous estrogen, levels of which are altered by OC, enhances cellular proliferation and the humoral immune system ( 25 ) and likely contributes to thrombosis that may lead to multifocal gastrointestinal infarction ( 26 ) . Although the precise pathophysiology of UC and CD remains largely unknown, these estrogen-mediated pathways may play a key role in etiology and progression of infl ammatory bowel disease. Epidemiologic studies have consistently shown an association between OC and risk of CD ( 10 ) . Recently, we also demonstrated an association between OC use, particularly the combination type, and risk of surgery among women with established CD ( 8 ) . In contrast, more recent studies indicate that there does not appear to be a link between OC use and risk of UC ( 9, 10 ) . Several older case series have reported acute severe self-resolving UC among younger women with recent initiation of OC (27) (28) (29) . However, TNF, tumor necrosis factor. a A total of 6,104 participants contributed person-years to this study with nearly 54% of women using oral contraceptives (OCs) through follow-up. Consists of methotrexate, azathioprine, and 6-mercaptopurine (6-MP). c Refers to use of infl iximab and adalimumab in Stockholm county only. OC information was updated every month, enabling us to account for signifi cant changes in the type or use of OC among younger women over time.
We acknowledge several limitations. First, despite our large sample size, we may not have had suffi cient statistical power to examine more modest associations between OC use and UC progression. However, most of our risk estimates were less than unity (inverse association); a larger sample size would be highly unlikely to yield positive associations. Moreover, even if weak our study is the fi rst to systematically assess the link between OC prescription and UC progression.
Our study has several strengths. First, the nationwide coverage of Swedish inpatient and outpatient and prescription registries off ers an opportunity to determine a more precise estimate of the association between OC use and risk of UC progression. Second, data were collected prospectively and this minimizes the risk of recall and selection biases that are typically evident in many case-control and cross-sectional studies. Finally, in our analyses, Adjusted for age (years), age at diagnosis (categories based on Table 1 ), number of encounters, education (≤9, 10-12, and ≥13 years), and health-care region of residence (categories based on Table 1 ).
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positive associations were present, their clinical signifi cance would likely be minimal. Second, voluntary childlessness among women with more severe disease may alter patterns of OC use. However, such a bias would have likely led to spurious associations between short-term use of OC and risk of surgery and/or steroid prescription. In contrast, in our primary analyses we did not observe any diff erences in risk of surgery or steroid prescription comparing OC users with nonusers. Th ird, we used surgery and steroid or anti-TNF prescriptions as a proxy for disease fl are and/or complication and were unable to specifi cally evaluate the short-term eff ect of OC use on disease activity using other clinical and endoscopic activity indices. In addition, steroid prescription data may not fully capture all episodes of UC fl ares. Fourth, we did not have information on smoking that has previously been linked to poor outcomes in UC ( 30, 31 ) . However as smoking is likely a negative confounder of the association between OC use and risk of UC complication (i.e., OC users are less likely to be current smokers), adjusting for smoking would have been unlikely to change the direction of the observed nonsignifi cant inverse association. Finally, information on OC use was only available aft er July of 2005 and therefore we were unable to fully capture cumulative use. However, our results were consistent across several sensitivity analyses. Specially starting our follow-up in June of 2006 (1 year aft er prescription registry was started) did not materially alter our eff ect estimates. In addition, stratifi ed analyses according to age, which could be a proxy for duration of OC use before July of 2005 not captured by prescription registry (e.g., younger women less likely to have been on OC for long period of time compared with older women), yielded similar risk estimates according to age groups.
In conclusion, we did not fi nd an association between OC use and risk of surgery and steroid or anti-TNF use among women with established UC. Our fi ndings provide reassurance that OC use does not negatively aff ect long-term progression of UC. ✓ Our data offer reassurance regarding the safety of oral contraceptives assessed by its effect on risk of surgery and steroid or anti-TNF use in women with established ulcerative colitis.
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